Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Helix BioPharma Corp. (T.HBP) had Consolidated Net Income/Loss of -1.35M for the most recently reported fiscal quarter, ending 2024-04-30.
| Income Statement Financials | |
-- |
|
-1.35M |
|
-- |
|
-- |
|
-- |
|
-1.34M |
|
-- |
|
-1.35M |
|
-1.35M |
|
-1.35M |
|
-1.35M |
|
|
Consolidated Net Income/Loss |
-1.35M |
-1.35M |
|
-1.34M |
|
-1.34M |
|
42.63M |
|
42.63M |
|
0.00 |
|
0.00 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
0.84M |
|
-- |
|
-- |
|
-- |
|
1.11M |
|
-0.63M |
|
-0.27M |
|
-0.27M |
|
45.89M |
|
| Cash Flow Statement Financials | |
-3.29M |
|
-0.01M |
|
3.25M |
|
0.60M |
|
0.52M |
|
-0.07M |
|
0.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.74 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-3.30M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
215.16% |
|
508.61% |
|
-159.91% |
|
508.61% |
|
-0.01 |
|
-0.08 |
|
-0.08 |
|